Latest Intelligence

Published within

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: breast cancer prospects receive a blow

Wyeth has discontinued a phase III trial of temsirolimus plus letrozole in metastatic post-menopausal hormone-receptor positive breast cancer. This is a significant blow for the company due to the loss of earnings potential in the congested but lucrative breast cancer market. However, temsirolimus remains under development for a number of other tumors, and so hope for the drug candidate remains.

Published By Datamonitor
23 Mar 2006
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
CommentWire
CommentWire

Wyeth: a question of consolidation

Revenues at Wyeth have climbed despite declining sales of key products such as Premarin and Prevnar. Litigation expenses continue to impact the bottom line, but a cash injection resulting from the merger of Immunex and Amgen has improved the company's financial situation. There are signs the company could be ripe for consolidation once more.

Published By Datamonitor
30 Jan 2003
CommentWire
CommentWire

Wyeth/MedImmune: the end of the road for FluMist venture

Following poor first-year performance, Wyeth [WYE] and MedImmune [MEDI] have announced the dissolution of their FluMist partnership. If MedImmune is to achieve success with this product alone, it may need to rethink its premium pricing strategy.

Published By Datamonitor
28 Apr 2004
CommentWire
CommentWire

Wyeth/MedImmune: second generation vaccine

Wyeth [WYE] and MedImmune's [MEDI] FluMist failed to secure indications for use in key target groups for influenza vaccine in the US. Recently released results suggest that their second generation product may enable the two companies to capitalize on more conventional influenza vaccine sectors.

Published By Datamonitor
15 Oct 2003
CommentWire
CommentWire

Wyeth Ayerst/Celltech: Mylotarg brings new hope

Published By Datamonitor
04 Dec 2000
CommentWire
CommentWire

Wyeth & Elan: hope grows for Alzheimer's treatment

Shares in Wyeth and Elan have risen following the release of much anticipated results for Alzheimer's treatment bapineuzumab. Although the primary endpoint was not met, the results suggest that the product may slow disease progression in approximately half of patients with a specific genetic make-up.

Published By Datamonitor
18 Jun 2008
Expert View
Expert View

Wunelli and SSP bet on the mass market

In the burgeoning telematics space Wunelli and SSP have partnered to launch a smartphone-based product targeting the mass market. The simplicity of such a solution will appeal to consumers, but data quality issues could limit the benefits to insurers.

Published By Datamonitor
14 May 2013
CommentWire
CommentWire

WSA: the friendlier face of alcohol regulation

In response to a government interim report on alcohol harm reduction, the WSA has released its own recommendations. Unsurprisingly, it argues against the more drastic actions the government proposes. However, the WSA's less costly suggestions are nothing new. They require little effort on the part of the industry and it is likely that they will also have little effect.

Published By Datamonitor
15 Dec 2003
CommentWire
CommentWire

WS-I consortium: candidates revealed

Nokia, Verisign, Sun, SeeBeyond, Cape Clear Software and webMethods are all vying for one of the two remaining places on the Web Services Interoperability board. Sun is emphasizing the Java angle, and is in a good position to take one of the seats, but most of its rivals have strong unique selling points too.

Published By Datamonitor
27 Feb 2003

« | ... | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ... | » »|

No help is available.